{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:29:56Z","timestamp":1786987796868,"version":"build-2736575974"},"reference-count":89,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["GR-2021-12374415"],"award-info":[{"award-number":["GR-2021-12374415"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.drudis.2025.104516","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:34:40Z","timestamp":1761550480000},"page":"104516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies"],"prefix":"10.1016","volume":"30","author":[{"given":"Erika","family":"Ferraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Macr\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Zwergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lambona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barillari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cassandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7007-4238","authenticated-orcid":false,"given":"Silvia","family":"Pomella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104516_b0005","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/pr.2012.54","article-title":"Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities","volume":"72","author":"Anderson","year":"2012","journal-title":"Pediatr Res"},{"key":"10.1016\/j.drudis.2025.104516_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.sempedsurg.2019.150862","article-title":"Recent progress in pediatric soft tissue sarcoma therapy","volume":"28","author":"Lautz","year":"2019","journal-title":"Semin Pediatr Surg"},{"key":"10.1016\/j.drudis.2025.104516_b0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3389\/fonc.2019.01078","article-title":"Epigenetic targets in synovial sarcoma: a mini-review","volume":"9","author":"Hale","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing sarcoma","volume":"4","author":"Grunewald","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2025.104516_b0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1615\/CritRevOncog.2015013800","article-title":"Pediatric rhabdomyosarcoma","volume":"20","author":"Shern","year":"2015","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.drudis.2025.104516_b0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-019-1038-1","article-title":"The expanding landscape of \u2018oncohistone\u2019 mutations in human cancers","volume":"567","author":"Nacev","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104516_b0035","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm.4273","article-title":"DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma","volume":"23","author":"Sheffield","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104516_b0040","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41379-018-0045-3","article-title":"Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information","volume":"31","author":"Koelsche","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.drudis.2025.104516_b0045","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911131","article-title":"Sarcoma treatment in the era of molecular medicine","volume":"12","author":"Grunewald","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2025.104516_b0050","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.3390\/ijms23073581","article-title":"Bromodomain inhibitor JQ1 provides novel insights and perspectives in rhabdomyosarcoma treatment","volume":"23","author":"Marchesi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104516_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104516_b0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104516_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106833","article-title":"Targeting the epigenetic reader \u201cBET\u201d as a therapeutic strategy for cancer","volume":"140","author":"Wahi","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2025.104516_b0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2025.104516_b0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cell.2011.01.024","article-title":"Functional and mechanistic diversity of distal transcription enhancers","volume":"144","author":"Bulger","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104516_b0080","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/molecules28073043","article-title":"BET bromodomain inhibitors: novel design strategies and therapeutic applications","volume":"28","author":"To","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104516_b0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1101\/gr.197590.115","article-title":"Models of human core transcriptional regulatory circuitries","volume":"26","author":"Saint-Andre","year":"2016","journal-title":"Genome Res"},{"key":"10.1016\/j.drudis.2025.104516_b0090","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.csbj.2021.05.006","article-title":"Super-enhancer-mediated core regulatory circuitry in human cancer","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.drudis.2025.104516_b0095","first-page":"437","article-title":"Management of the HIV-infected patient","volume":"84","author":"Bryan","year":"1988","journal-title":"J S C Med Assoc"},{"key":"10.1016\/j.drudis.2025.104516_b0100","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104516_b0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/1574892812666170808121228","article-title":"BET inhibitors as anticancer agents: a patent review","volume":"12","author":"Ali","year":"2017","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.drudis.2025.104516_b0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.phrs.2017.11.015","article-title":"Targeting bromodomain and extraterminal proteins in breast cancer","volume":"129","author":"Sahni","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2025.104516_b0115","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2174\/0115680096272757231211113206","article-title":"Bromodomain protein-directed agents and MYC in small cell lung cancer","volume":"24","author":"Hamilton","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2025.104516_b0120","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41588-019-0534-4","article-title":"Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma","volume":"51","author":"Gryder","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2025.104516_b0125","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1158\/2159-8290.CD-16-1297","article-title":"PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability","volume":"7","author":"Gryder","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104516_b0130","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/0008-5472.CAN-18-0484","article-title":"EWS\/ETS-driven Ewing sarcoma requires BET bromodomain proteins","volume":"78","author":"Gollavilli","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104516_b0135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1590\/S0074-02761990000200017","article-title":"Food sources of Culex quinquefasciatus Say, 1823 (Diptera: Culicidae) in Machurrucutu locality, Havana Province, Cuba","volume":"85","author":"Castex","year":"1990","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.drudis.2025.104516_b0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.31083\/ph.2018.8480","article-title":"JQ1: a novel potential therapeutic target","volume":"73","author":"Shi","year":"2018","journal-title":"Pharmazie"},{"key":"10.1016\/j.drudis.2025.104516_b0145","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2022.102148","article-title":"BET bromodomain inhibitors","volume":"68","author":"Schwalm","year":"2022","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.drudis.2025.104516_b0155","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/acsptsci.3c00219","article-title":"Apabetalone (RVX-208): a potential epigenetic therapy for the treatment of cardiovascular, renal, neurological, viral, and cancer disorders","volume":"7","author":"Dhulkifle","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2025.104516_b0160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104516_b0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0170","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1535-7163.MCT-15-0074","article-title":"Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression","volume":"14","author":"Teicher","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104516_b0175","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/CCO.0000000000001048","article-title":"Emerging therapies in Ewing sarcoma","volume":"36","author":"Strauss","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005415","article-title":"A molecular function map of Ewing\u2019s sarcoma","volume":"4","author":"Kauer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104516_b0185","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1002\/cncr.25840","article-title":"Clinical features and outcomes in patients with extraskeletal Ewing sarcoma","volume":"117","author":"Applebaum","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2025.104516_b0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00428-019-02720-8","article-title":"Ewing sarcoma and Ewing-like tumors","volume":"476","author":"Sbaraglia","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.drudis.2025.104516_b0195","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/359162a0","article-title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","volume":"359","author":"Delattre","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104516_b0200","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1054\/bjoc.2000.1652","article-title":"Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes","volume":"84","author":"Matsumoto","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2025.104516_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2005.08.007","article-title":"EWS-ETS oncoproteins: the linchpins of Ewing tumors","volume":"363","author":"Janknecht","year":"2005","journal-title":"Gene"},{"key":"10.1016\/j.drudis.2025.104516_b0210","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.4161\/15592294.2014.988048","article-title":"Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs","volume":"9","author":"Svoboda","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.drudis.2025.104516_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100404","article-title":"One oncogene, several vulnerabilities: EWS\/FLI targeted therapies for Ewing sarcoma","volume":"31","author":"Flores","year":"2021","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0220","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/epi-2019-0172","article-title":"BET bromodomains\u2019 functions in bone-related pathologies","volume":"12","author":"Jacques","year":"2020","journal-title":"Epigenomics"},{"key":"10.1016\/j.drudis.2025.104516_b0225","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.18632\/oncotarget.6385","article-title":"Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma","volume":"7","author":"Hensel","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104516_b0230","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1073\/pnas.1613091114","article-title":"Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis","volume":"114","author":"Andrews","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104516_b0235","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ccell.2015.05.006","article-title":"Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy","volume":"27","author":"Stratikopoulos","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104516_b0240","doi-asserted-by":"crossref","first-page":"24125","DOI":"10.18632\/oncotarget.8214","article-title":"Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS\/Fli1","volume":"7","author":"Jacques","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104516_b0245","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/1535-7163.MCT-15-0567","article-title":"The Bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma","volume":"15","author":"Bid","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104516_b0250","doi-asserted-by":"crossref","first-page":"43504","DOI":"10.18632\/oncotarget.9762","article-title":"BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma","volume":"7","author":"Loganathan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104516_b0255","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nm.3613","article-title":"Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition","volume":"20","author":"Tang","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104516_b0260","first-page":"e1163","article-title":"Combinatorial BRD4 and AURKA inhibition is synergistic against preclinical models of Ewing sarcoma","volume":"2","author":"Tomino","year":"2019","journal-title":"Cancer Rep"},{"key":"10.1016\/j.drudis.2025.104516_b0265","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/cancers12020304","article-title":"Combined inhibition of epigenetic readers and transcription initiation targets the EWS-ETS transcriptional program in Ewing sarcoma","volume":"12","author":"Richter","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104516_b0270","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1097\/MPH.0000000000002054","article-title":"Augmented antitumor activity for novel dual PI3K\/BDR4 inhibitors, SF2523 and SF1126 in Ewing sarcoma","volume":"43","author":"Goldin","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0275","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000489556","article-title":"Gastrointestinal stromal tumors: clinical symptoms, location, metastasis formation, and associated malignancies in a single center retrospective study","volume":"36","author":"Aghdassi","year":"2018","journal-title":"Dig Dis"},{"key":"10.1016\/j.drudis.2025.104516_b0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2025.104516_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100959","article-title":"Genomic profiling in GIST: implications in clinical outcome and future challenges","volume":"48","author":"Calderillo-Ruiz","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.drudis.2025.104516_b0290","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.3390\/jcm13143997","article-title":"Understanding gastric GIST: from pathophysiology to personalized treatment","volume":"13","author":"Moga","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2025.104516_b0295","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/0008-5472.CAN-18-1888","article-title":"Enhancer domains in gastrointestinal stromal tumor regulate KIT expression and are targetable by BET bromodomain inhibition","volume":"79","author":"Hemming","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104516_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151654","article-title":"Osteosarcoma: a comprehensive review of management and treatment strategies","volume":"49","author":"Jafari","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.drudis.2025.104516_b0305","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.hoc.2025.04.005","article-title":"Osteosarcoma: diagnosis, treatment, and emerging opportunities","volume":"39","author":"Bishop","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.drudis.2025.104516_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1615111","article-title":"The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma","volume":"19","author":"Su","year":"2025","journal-title":"Oncol Rev"},{"key":"10.1016\/j.drudis.2025.104516_b0315","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.3390\/cancers15123247","article-title":"RUNX family as a promising biomarker and a therapeutic target in bone cancers: a review on its molecular mechanism(s) behind tumorigenesis","volume":"15","author":"Vimalraj","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104516_b0320","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1038\/ncomms4511","article-title":"Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle","volume":"5","author":"Lamoureux","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104516_b0325","doi-asserted-by":"crossref","first-page":"25887","DOI":"10.1021\/acsami.7b08108","article-title":"Bisphosphonate-functionalized hydroxyapatite nanoparticles for the delivery of the bromodomain inhibitor JQ1 in the treatment of osteosarcoma","volume":"9","author":"Wu","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2025.104516_b0330","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nm.4475","article-title":"Positively selected enhancer elements endow osteosarcoma cells with metastatic competence","volume":"24","author":"Morrow","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104516_b0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41413-018-0009-8","article-title":"Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma","volume":"6","author":"Chen","year":"2018","journal-title":"Bone Res"},{"key":"10.1016\/j.drudis.2025.104516_b0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/cancers15010259","article-title":"Integrative Multi-OMICs identifies therapeutic response biomarkers and confirms fidelity of clinically annotated, serially passaged patient-derived xenografts established from primary and metastatic pediatric and AYA solid tumors","volume":"15","author":"Pandya","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104516_b0345","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1186\/s12885-024-12691-y","article-title":"The BET PROTAC inhibitor GNE-987 displays anti-tumor effects by targeting super-enhancers regulated gene in osteosarcoma","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2025.104516_b0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.path.2024.10.005","article-title":"Rhabdomyosarcoma classification: refining our understanding","volume":"18","author":"Rubrecht","year":"2025","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.drudis.2025.104516_b0355","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1570070","article-title":"Fusion oncogenes in rhabdomyosarcoma: model systems, mechanisms of tumorigenesis, and therapeutic implications","volume":"15","author":"Sankhe","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0360","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.3390\/cancers15215269","article-title":"Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatment strategies","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104516_b0365","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2018.04.032","article-title":"Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells","volume":"428","author":"Enssle","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104516_b0370","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1038\/s41388-020-1229-0","article-title":"Co-inhibition of BET proteins and PI3Kalpha triggers mitochondrial apoptosis in rhabdomyosarcoma cells","volume":"39","author":"Boedicker","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104516_b0375","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.18632\/oncotarget.2726","article-title":"Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma","volume":"6","author":"Graab","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104516_b0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2020.03.011","article-title":"BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells","volume":"479","author":"Camero","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104516_b0385","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2020.05.008","article-title":"The novel dual BET\/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells","volume":"486","author":"Laszig","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104516_b0390","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neo.2021.11.012","article-title":"Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells","volume":"24","author":"Erdogdu","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.drudis.2025.104516_b0395","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mc.23414","article-title":"Combined inhibition of BET bromodomain and mTORC1\/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism","volume":"61","author":"Srivastava","year":"2022","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.drudis.2025.104516_b0400","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/1535-7163.MCT-20-0625","article-title":"Redundant signaling as the predominant mechanism for resistance to antibodies targeting the type-I insulin-like growth factor receptor in cells derived from childhood sarcoma","volume":"22","author":"Shackleford","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104516_b0405","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jcp.25427","article-title":"Targeting the breast cancer kinome","volume":"232","author":"Miller","year":"2017","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2025.104516_b0410","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s44319-023-00033-1","article-title":"BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma","volume":"25","author":"Das","year":"2024","journal-title":"EMBO Rep"},{"key":"10.1016\/j.drudis.2025.104516_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101618","article-title":"Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies","volume":"8","author":"Blay","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.drudis.2025.104516_b0420","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/curroncol28030177","article-title":"Synovial sarcoma: a clinical review","volume":"28","author":"Gazendam","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0425","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPH.0000000000000154","article-title":"Synovial sarcoma in children and adolescents","volume":"36","author":"Kerouanton","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.drudis.2025.104516_b0430","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/cancers16061125","article-title":"Therapeutic potential of bromodomain and extra-terminal domain inhibitors for synovial sarcoma cells","volume":"16","author":"Kotani","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104516_b0435","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41467-019-14083-4","article-title":"Enhanced JunD\/RSK3 signalling due to loss of BRD4\/FOXD3\/miR-548d-3p axis determines BET inhibition resistance","volume":"11","author":"Tai","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104516_b0440","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/acs.jmedchem.4c00141","article-title":"Peptide inhibitor targeting the extraterminal domain in BRD4 potently suppresses breast cancer both in vitro and in vivo","volume":"67","author":"Huang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104516_b0445","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1002\/cncr.35457","article-title":"Roadmap for the next generation of Children\u2019s Oncology Group rhabdomyosarcoma trials","volume":"130","author":"Metts","year":"2024","journal-title":"Cancer"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:07:58Z","timestamp":1780920478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1359644625002296"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104516","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104516"}}